BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, October 19, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» BI-894416, a highly selective SYK inhibitor with efficacy in OVA-induced asthma rat model
To read the full story,
subscribe
or
sign in
.
Respiratory
BI-894416, a highly selective SYK inhibitor with efficacy in OVA-induced asthma rat model
Sep. 23, 2024
No Comments
Researchers from Boehringer Ingelheim Pharma GmbH & Co KG presented the discovery and preclinical characterization of new spleen tyrosine kinase (SYK) inhibitors, BI-894416 and BI-1342561, being developed for the treatment of asthma.
BioWorld Science
Conferences
Respiratory